RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus
RAPT Therapeutics held steady on Wednesday, trading around $57.60 midday on Nasdaq. The shares ticked up just 0.05% during the session.
GSK share price steadies as $2.2bn RAPT deal lands amid fresh U.S. vaccine-policy risk
GSK shares ticked up in early London trading Thursday as investors weighed the drugmaker’s push into a mid-stage food-allergy treatment alongside growing discussions over vaccine demand in the U.S.
GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open
GSK plc’s U.S.-listed shares slipped 1.2% to $47.65 in light premarket trading Wednesday, following the announcement of a $2.2 billion acquisition and changes at its HIV joint venture.
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share
Rapt Therapeutics surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech.
RAPT stock price jumps as GSK strikes $2.2 billion buyout for food allergy drug
RAPT Therapeutics shares jumped about 64% Tuesday, reaching $57.54 in early Nasdaq action. The uptick followed Britain’s GSK unveiling a cash acquisition offer of $58 per share for the U.S. biotech firm.
TechStock² Updates
